CY1124307T1 - Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων - Google Patents

Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων

Info

Publication number
CY1124307T1
CY1124307T1 CY20211100523T CY211100523T CY1124307T1 CY 1124307 T1 CY1124307 T1 CY 1124307T1 CY 20211100523 T CY20211100523 T CY 20211100523T CY 211100523 T CY211100523 T CY 211100523T CY 1124307 T1 CY1124307 T1 CY 1124307T1
Authority
CY
Cyprus
Prior art keywords
therapy
methods
pharmaceutical composition
sglt
complications
Prior art date
Application number
CY20211100523T
Other languages
English (en)
Inventor
Uli Broedl
Maximilian VON EYNATTEN
Odd-Erik JOHANSEN
Thomas Klein
Gerd Luippold
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46420221&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1124307(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of CY1124307T1 publication Critical patent/CY1124307T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Η εφεύρεση αφορά την θεραπεία ή την πρόληψη της νεφρικής δυσλειτουργίας και/ή επιπλοκών, χρησιμοποιώντας έναν αναστολέα SGLT-2, για παράδειγμα σε ασθενείς που έχουν διαγνωστεί με μεταβολικές διαταραχές και συναφείς παθήσεις.
CY20211100523T 2011-07-08 2021-06-14 Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων CY1124307T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161505598P 2011-07-08 2011-07-08
PCT/EP2012/062922 WO2013007557A1 (en) 2011-07-08 2012-07-03 Pharmaceutical composition, methods for treating and uses thereof

Publications (1)

Publication Number Publication Date
CY1124307T1 true CY1124307T1 (el) 2022-07-22

Family

ID=46420221

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100523T CY1124307T1 (el) 2011-07-08 2021-06-14 Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων

Country Status (22)

Country Link
US (5) US20130035298A1 (el)
EP (2) EP2729151B1 (el)
JP (2) JP2014520778A (el)
KR (1) KR20140041697A (el)
CN (2) CN103732230A (el)
AR (1) AR087729A1 (el)
AU (1) AU2012283229B2 (el)
BR (1) BR112014000380A2 (el)
CA (1) CA2837787C (el)
CY (1) CY1124307T1 (el)
DK (1) DK2729151T3 (el)
EA (1) EA025497B1 (el)
ES (1) ES2871904T3 (el)
HR (1) HRP20210978T1 (el)
HU (1) HUE054621T2 (el)
LT (1) LT2729151T (el)
MX (1) MX2014000010A (el)
PL (1) PL2729151T3 (el)
PT (1) PT2729151T (el)
RS (1) RS61827B1 (el)
SI (1) SI2729151T1 (el)
WO (1) WO2013007557A1 (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
PE20090938A1 (es) * 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
NZ594487A (en) 2009-02-13 2013-11-29 Boehringer Ingelheim Int Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
IN2012DN02751A (el) 2009-09-30 2015-09-18 Boehringer Ingelheim Int
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303098A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2812519A1 (en) * 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
ES2906115T3 (es) 2013-04-18 2022-04-13 Boehringer Ingelheim Int Composición farmacéutica, métodos de tratamiento y usos de la misma
WO2015101916A1 (en) 2013-12-30 2015-07-09 Mylan Laboratories Ltd. Process for the preparation of empagliflozin
EP4234012A3 (en) * 2014-01-23 2023-09-20 Boehringer Ingelheim Vetmedica GmbH Sglt2 inhibitors for treatment of metabolic disorders in canine animals
CN106103407B (zh) 2014-03-04 2020-10-16 大塚制药株式会社 碘海醇粉末及其使用方法
WO2016051368A1 (en) * 2014-10-01 2016-04-07 Mylan Laboratories Ltd Complex of amorphous empagliflozin and a cyclodextrin
WO2016156124A1 (en) * 2015-03-27 2016-10-06 F. Hoffmann-La Roche Ag Pharmaceutical formulation comprising sembragiline
MX2018011088A (es) * 2016-03-16 2018-11-22 Boehringer Ingelheim Int Composicion farmaceutica que comprende empagliflozina y sus usos.
CN109922813A (zh) * 2016-11-10 2019-06-21 勃林格殷格翰国际有限公司 药物组合物、治疗方法及其用途
WO2020089761A1 (en) * 2018-11-01 2020-05-07 Glenmark Pharmaceuticals Limited Pharmaceutical composition comprising of remogliflozin or salt or ester thereof and vildagliptin or salt thereof
US11655240B1 (en) * 2022-05-10 2023-05-23 Beijing Grand Johamu Pharmaceutical Company, Ltd. Crystal form of compound and fumaric acid, pharmaceutical composition and method for treating coronavirus-induced diseases

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
EP2295422A3 (de) 2004-03-16 2012-01-04 Boehringer Ingelheim International GmbH Glucopyranosylsubstituierte Benzolderivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
JP2008524162A (ja) 2004-12-16 2008-07-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換ベンゼン誘導体、該化合物を含む薬物、その使用及びその製造方法
UA91546C2 (uk) * 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7723309B2 (en) 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
US8183340B2 (en) 2005-05-13 2012-05-22 Eli Lilly And Company GLP-1 pegylated compounds
CA2620566A1 (en) 2005-08-30 2007-03-08 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
RU2008113050A (ru) 2005-09-08 2009-10-20 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-(4-ЭТИНИЛБЕНЗИН)-БЕНЗОЛА, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ
AR056195A1 (es) 2005-09-15 2007-09-26 Boehringer Ingelheim Int Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
US7745414B2 (en) 2006-02-15 2010-06-29 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
US8039441B2 (en) 2006-08-15 2011-10-18 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture
US8283326B2 (en) 2006-10-27 2012-10-09 Boehringer Ingelheim International Gmbh Crystalline form of 4-(beta-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
JP2010508371A (ja) 2006-11-06 2010-03-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換フェニル誘導体、該化合物を含有する医薬品及びその使用と製造方法
BRPI0718596B8 (pt) 2006-11-09 2021-05-25 Boehringer Ingelheim Int composições farmacêuticas para terapia de combinação com inibidores de sglt-2 e metformina
EP3260129A1 (en) 2007-08-03 2017-12-27 Eli Lilly and Company An fgf-21 compound and a glp-1 compound for use in the treatment of obesity
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
NZ594487A (en) 2009-02-13 2013-11-29 Boehringer Ingelheim Int Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
UA106365C2 (ru) 2009-02-13 2014-08-26 Берингер Ингельхайм Интернациональ Гмбх Способ улучшения гликемического контроля и способ снижения жира в организме с применением ингибитора sglt-2
UY32427A (es) 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
IN2012DN02751A (el) 2009-09-30 2015-09-18 Boehringer Ingelheim Int
WO2011039107A1 (en) 2009-09-30 2011-04-07 Boehringer Ingelheim International Gmbh Method for the preparation of a crystalline form of 1-chloro-4- (beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof

Also Published As

Publication number Publication date
EP3854404A1 (en) 2021-07-28
DK2729151T3 (da) 2021-06-28
EA025497B1 (ru) 2016-12-30
EP2729151B1 (en) 2021-03-31
MX2014000010A (es) 2014-02-27
ES2871904T3 (es) 2021-11-02
NZ618546A (en) 2016-02-26
AU2012283229A1 (en) 2014-01-09
SI2729151T1 (sl) 2021-06-30
AU2012283229B2 (en) 2017-06-15
LT2729151T (lt) 2021-05-25
PT2729151T (pt) 2021-05-25
CN103732230A (zh) 2014-04-16
PL2729151T3 (pl) 2021-10-18
EA201400119A1 (ru) 2014-08-29
US20130035298A1 (en) 2013-02-07
CA2837787A1 (en) 2013-01-17
CN106692126A (zh) 2017-05-24
WO2013007557A1 (en) 2013-01-17
AR087729A1 (es) 2014-04-16
US20180214468A1 (en) 2018-08-02
JP2016121156A (ja) 2016-07-07
HUE054621T2 (hu) 2021-09-28
CA2837787C (en) 2021-09-14
US20200268777A1 (en) 2020-08-27
RS61827B1 (sr) 2021-06-30
US20220096505A1 (en) 2022-03-31
KR20140041697A (ko) 2014-04-04
JP2014520778A (ja) 2014-08-25
US20230405032A1 (en) 2023-12-21
HRP20210978T1 (hr) 2021-09-17
BR112014000380A2 (pt) 2017-02-14
EP2729151A1 (en) 2014-05-14

Similar Documents

Publication Publication Date Title
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
CY1121203T1 (el) Θεραπευτικες χρησεις της εμπαγλιφλοζινης
CY1124311T1 (el) Παρεμποδιστες dna-pk
CY1121882T1 (el) Αναστολεις πυραζολυλο κινοξαλινο κινασης
CY1124298T1 (el) Φενφλουραμινη για χρηση στην θεραπευτικη αντιμετωπιση του συνδρομου dravet
CY1125436T1 (el) Αναστολεις dna-pk
CY1123552T1 (el) Θεραπειες συνδυασμου με χρηση μοριων προσδεσης psl και pcrv αντι- pseudomonas
CY1123051T1 (el) Ταπενταδολη για προληψη και θεραπεια καταθλιψης και αγχους
CY1120102T1 (el) Συνθεσεις και μεθοδοι για μειωση τριγλυκεριδιων χωρις αυξηση επιπεδων ldl-c σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
CY1121170T1 (el) Νεες ενωσεις ως ρυθμιστες πρωτεϊνικων κινασων
CY1121150T1 (el) Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
CY1117678T1 (el) Ενωσεις αναστολεων μεταλλοενζυμου
MX346224B (es) Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias.
BR112013021863A2 (pt) anticorpos anti-receptor il-6 e métodos de uso
BR112014021498A2 (pt) composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
EA201490748A1 (ru) Лечение рассеянного склероза комбинацией лахинимода и финголимода
MX343534B (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
EA201490194A1 (ru) Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека
TR201904980T4 (tr) Bir B-Raf inhibitörü, bir EGFR inhibitörü ve isteğe bağlı olarak bir PI3K-alfa inhibitörü içeren farmasötik kombinasyonlar.
CY1120751T1 (el) Αναστολεις ετεροδικυκλοαρυλιου του rorc2 και μεθοδοι χρησης αυτων
EA201301107A1 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
EA201590359A1 (ru) Лечение ревматоидного артрита
CY1123490T1 (el) Συνθεσεις που προερχονται απο χιτοζανη